Mechanisms of cardiac dysfunction in obstructive sleep apnea

Nature Reviews Cardiology

Volumn 9, Issue 12, 2012, Pages 679-688

  Baguet, Jean Philippe ^a   Barone Rochette, Gilles ^a   Tamisier, Renaud ^b   Levy, Patrick ^b   Pépin, Jean Louis ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b University Grenoble Alpes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD31 ANTIGEN; ENDOTHELIN 1; LEPTIN; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; RANTES; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; HUMAN; HYPERCAPNIA; HYPERCOAGULABILITY; HYPERINSULINISM; HYPERTENSION; HYPERTENSIVE HEART DISEASE; HYPOXEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LIPID PEROXIDATION; META ANALYSIS; MICROCIRCULATION; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRESSORECEPTOR REFLEX; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; RISK FACTOR; RISK REDUCTION; SLEEP DISORDERED BREATHING; SYMPTOM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TACHYCARDIA INDUCED CARDIOMYOPATHY; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

CARDIOVASCULAR DISEASES; HUMANS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84870239687     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.141     Document Type: Review

References (139)

1. Young, T., Peppard, P. E. & Gottlieb, D. J. Epidemiology of obstructive sleep apnea: a population health perspective. Am. J. Respir. Crit. Care Med. 165, 1217-1239 (2002).
2. Parati, G. et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Cooperation in Scientific and Technological Research) ACTION B26 on obstructive sleep apnea. J. Hypertens. 30, 633-646 (2012).
3. Iber, C., Anconi-Israel, S., Chesson, A. L. & Quan, S. F. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications (American Academy of Sleep Medicine, Westchester, 2007).
4. Gottlieb, D. J. et al. Relation of sleepiness to respiratory disturbance index: the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 159, 502-507 (1999).
5. Mazza, S. et al. Most obstructive sleep apnoea patients exhibit vigilance and attention deficits on an extended battery of tests. Eur. Respir. J. 25, 75-80 (2005).
6. Leung, R. S. & Bradley, T. D. Sleep apnea and cardiovascular disease. Am. J. Respir. Crit. Care Med. 164, 2147-2165 (2001).
7. Wolk, R., Kara, T. & Somers, V. K. Sleep-disordered breathing and cardiovascular disease. Circulation 108, 9-12 (2003).
8. Young, T. et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch. Intern. Med. 157, 1746-1752 (1997).
9. Nieto, J. et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 283, 1829-1836 (2000).
10. Peppard, P. E., Young, T., Palta, M. & Skatrud, J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342, 1378-1384 (2000).
11. Baguet, J.-P. et al. Night-time and diastolic hypertension are common and underestimated conditions in newly diagnosed apnoeic patients. J. Hypertens. 23, 521-527 (2005).
12. Peker, Y., Hedner, J., Kraiczi, H. & Löth, S. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am. J. Respir. Crit. Care Med. 162, 81-86 (2000).
13. Mooe, T., Franklin, K. A., Holmström, K., Rabben, T. & Wiklund, U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am. J. Respir. Crit. Care Med. 164, 1910-1913 (2001).
14. Milleron, O. et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur. Heart J. 25, 728-734 (2004).
15. Yaggi, H. K. et al. Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 353, 2034-2041 (2005).
16. Kanagala, R. et al. Sleep apnea and the recurrence of atrial fibrillation. Circulation 107, 2589-2594 (2003).
17. Gami, A. S. et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110, 364-367 (2004).
18. Marin, J. M., Carrizo, S. J., Vicente, E. & Agusti, A. G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365, 1046-1053 (2005).
19. Kohler, M. & Stradling, J. R. Mechanisms of vascular damage in obstructive sleep apnea. Nat. Rev. Cardiol. 7, 677-685 (2010).
20. Somers, V. K. et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J. Am. Coll. Cardiol. 52, 686-717 (2008).
21. Gottlieb, D. J. et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 122, 352-360 (2010).
22. Leech, J. A., Onal, E. & Lopata, M. Nasal CPAP continues to improve sleep-disordered breathing and daytime oxygenation over long-term follow-up of occlusive sleep apnea syndrome. Chest 102, 1651-1655 (1992).
23. Shivalkar, B. et al. Obstructive sleep apnea syndrome: more insights on structural and functional cardiac alterations, and the effects of treatment with continuous positive airway pressure. J. Am. Coll. Cardiol. 47, 1433-1439 (2006).
24. Dursunoglu, N. et al. Effects of CPAP on left ventricular structure and myocardial performance index in male patients with obstructive sleep apnoea. Sleep Med. 8, 51-59 (2007).
25. Kohler, M. et al. CPAP and measures of cardiovascular risk in males with OSAS. Eur. Respir. J. 32, 1488-1496 (2008).
26. Barbé, F. et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 307, 2161-2168 (2012).
27. Hsu, C. Y. et al. Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J. Neurol. Neurosurg. Psychiatry 77, 1143-1149 (2006).
28. Craig, S. et al. Continuous positive airway pressure treatment for obstructive sleep apnoea reduces resting heart rate but does not affect dysrhythmias: a randomised controlled trial. J. Sleep Res. 18, 329-336 (2009).
29. Marin, J. M. et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 307, 2169-2176 (2012).
30. Chobanian, A. V. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
31. Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007).
32. Logan, A. G. et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J. Hypertens. 19, 2271-2277 (2001).
33. Baguet, J.-P. et al. Masked hypertension in obstructive sleep apnea syndrome. J. Hypertens. 26, 885-892 (2008).
34. Hla, K. M. et al. Longitudinal association of sleep-disordered breathing and nondipping of nocturnal blood pressure in the Wisconsin Sleep Cohort Study. Sleep 31, 795-800 (2008).
35. Grote, L., Hedner, J. & Peter, J. H. Mean blood pressure, pulse pressure and grade of hypertension in untreated hypertensive patients with sleep-related breathing disorder. J. Hypertens. 19, 683-690 (2001).
36. Somers, V. K., Dyken, M. E., Clary, M. P. & Abboud, F. M. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 96, 1897-1904 (1995).
37. Greenberg, H. E., Sica, A., Batson, D. & Scharf, S. M. Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. J. Appl. Physiol. 86, 298-305 (1999).
38. Brooks, D., Horner, R. L., Kozar, L. F., Render-Teixeira, C. L. & Phillipson, E. A. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J. Clin. Invest. 99, 106-109 (1997).
39. Dimsdale, J. E., Coy, T., Ziegler, M. G., Ancoli-Israel, S. & Clausen, J. The effect of sleep apnea on plasma and urinary catecholamines. Sleep 18, 377-381 (1995).
40. Kato, M. et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102, 2607-2610 (2000).
41. Shamsuzzaman, A. S. et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105, 2462-2464 (2002).
42. Yokoe, T. et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107, 1129-1134 (2003).
43. Minoguchi, K. et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 172, 625-630 (2005).
44. Jelic, S. et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 117, 2270-2278 (2008).
45. Lavie, L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med. Rev. 7, 35-51 (2003).
46. Dyugovskaya, L., Lavie, P. & Lavie, L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 165, 934-939 (2002).
47. Troncoso-Brindeiro, C. M., da-Silva, A. Q., Allahdadi, K. J., Youngblood, V. & Kanagy, N. L. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am. J. Physiol. Heart Circ. Physiol. 293, H2971-H2976 (2007).
48. Faure, P. et al. Impairment of serum albumin antioxidant properties in obstructive sleep apnoea syndrome. Eur. Respir. J. 31, 1046-1053 (2008).
49. Moller, D. S., Lind, P., Strunge, B. & Pedersen, E. B. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am. J. Hypertens. 16, 274-280 (2003).
50. Phillips, B. G., Kato, M., Narkiewicz, K., Choe, I. & Somers, V. K. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 279, H234-H237 (2000).
51. Drager, L. F. et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS ONE 5, e12065 (2010).
52. Bonsignore, M. R. et al. Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea. Eur. Respir. J. 39, 1136-1143 (2012).
53. Kanagy, N. L., Walker, B. R. & Nelin, L. D. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 37, 511-515 (2001).
54. Ryan, S., Ward, S., Heneghan, C. & McNicholas, W. T. Predictors of decreased spontaneous baroreflex sensitivity in obstructive sleep apnea syndrome. Chest 131, 1100-1107 (2007).
55. Durán-Cantolla, J. et al. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ 341, c5991 (2010).
56. Bazzano, L. A., Khan, Z., Reynolds, K. & He, J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 50, 417-423 (2007).
57. Haentjens, P. et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome. Arch. Intern. Med. 167, 757-765 (2007).
58. Hedner, J., Darpö, B., Ejnell, H., Carlson, J. & Caidahl, K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur. Respir. J. 8, 222-229 (1995).
59. Imadojemu, V. A. et al. Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am. J. Respir. Crit. Care Med. 165, 950-953 (2002).
60. Kraiczi, H., Hedner, J., Peker, Y. & Grote, L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 161, 1423-1428 (2000).
61. Pépin, J.-L. et al. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am. J. Respir. Crit. Care Med. 182, 954-960 (2010).
62. Haider, A. W., Larson, M. G., Franklin, S. S. & Levy, D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann. Intern. Med. 138, 10-16 (2003).
63. Schillaci, G. et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35, 580-586 (2000).
64. Verdecchia, P. et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81, 528-536 (1990).
65. Hedner, J., Ejnell, H. & Caidahl, K. Left ventricular hypertrophy independent of hypertension in patients with obstructive sleep apnoea. J. Hypertens. 8, 941-946 (1990).
66. Kraiczi, H., Peker, Y., Caidahl, K., Samuelsson, A. & Hedner, J. Blood pressure, cardiac structure and severity of obstructive sleep apnea in a sleep clinic population. J. Hypertens. 19, 2071-2078 (2001).
67. Chami, H. A. et al. Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health Study. Circulation 117, 2599-2607 (2008).
68. Noda, A., Okada, T., Yasuma, F., Nakashima, N. & Yokota, M. Cardiac hypertrophy in obstructive sleep apnea syndrome. Chest 107, 1538-1544 (1995).
69. Baguet, J.-P. et al. Left ventricular diastolic dysfunction is linked to severity of obstructive sleep apnoea. Eur. Respir. J. 36, 1323-1329 (2010).
70. Kraiczi, H., Caidahl, K., Samuelsson, A., Peker, Y. & Hedner, J. Impairment of vascular endothelial function and left ventricular filling. Association with the severity of apnea-induced hypoxemia during sleep. Chest 119, 1085-1091 (2001).
71. Dursunoglu, D. et al. Impact of obstructive sleep apnea on left ventricular mass and global function. Eur. Respir. J. 26, 283-288 (2005).
72. Chen, L. et al. Left ventricular dysfunction and associated cellular injury in rats exposed to chronic intermittent hypoxia. J. Appl. Physiol. 104, 218-223 (2008).
73. Hayashi, T. et al. Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. Am. J. Physiol. Heart Circ. Physiol. 294, H2197-H2203 (2008).
74. López, B. et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38, 1222-1226 (2001).
75. Marney, A. M. & Brown, N. J. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 113, 267-278 (2007).
76. Pratt-Ubunama, M. N. et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131, 453-459 (2007).
77. Vautrin, E. et al. Procollagen type III amino terminal peptide (PIIIP) is associated with left ventricular diastolic dysfunction in obstructive sleep apnoea. Int. J. Cardiol. 151, 387-388 (2011).
78. Levin, E. R., Gardner, D. G. & Samson, W. K. Natriuretic peptides. N. Engl. J. Med. 339, 321-328 (1998).
79. Svatikova, A. et al. Plasma brain natriuretic peptide in obstructive sleep apnea. Am. J. Cardiol. 94, 529-532 (2004).
80. Patwardhan, A. A. et al. Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. Sleep 29, 1301-1306 (2006).
81. Usui, Y. et al. Plasma B-type natriuretic peptide level is associated with left ventricular hypertrophy among obstructive sleep apnoea patients. J. Hypertens. 26, 117-123 (2008).
82. Cifçi, N., Uyar, M., Elbek, O., Süyür, H. & Ekinci, E. Impact of CPAP treatment on cardiac biomarkers and pro-BNP in obstructive sleep apnea syndrome. Sleep Breath. 14, 241-244 (2010).
83. Colish, J. et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest 141, 674-681 (2012).
84. Peker, Y., Carlson, J. & Hedner, J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur. Respir. J. 28, 596-602 (2006).
85. Nakashima, H. et al. Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. Eur. Heart J. 27, 2317-2322 (2006).
86. Arnaud, C. et al. The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am. J. Respir. Crit. Care Med. 184, 724-731 (2011).
87. Dematteis, M. et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am. J. Respir. Crit. Care Med. 177, 227-235 (2008).
88. Tzima, E. et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437, 426-431 (2005).
89. Oga, T. et al. Effects of obstructive sleep apnea with intermittent hypoxia on platelet aggregability. J. Atheroscler. Thromb. 16, 862-869 (2009).
90. Terada, S. et al. Abnormal coagulation and platelet profile in patients with obstructive sleep apnea syndrome. Int. J. Cardiol. 146, 423-425 (2011).
91. Monneret, D. et al. Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients. Free Radic. Biol. Med. 48, 619-625 (2010).
92. Savransky, V. et al. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 175, 1290-1297 (2007).
93. Baguet, J.-P. et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 128, 3407-3412 (2005).
94. Ip, M. S., Tse, H. F., Lam, B., Tsang, K. W. & Lam, W. K. Endothelial function in obstructive sleep apnea and response to treatment. Am. J. Respir. Crit. Care Med. 169, 348-353 (2004).
95. Itzhaki, S., Lavie, L., Pillar, G., Tal, G. & Lavie, P. Endothelial dysfunction in obstructive sleep apnea measured by peripheral arterial tone response in the finger to reactive hyperemia. Sleep 28, 594-600 (2005).
96. Butt, M. et al. Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in obstructive sleep apnea. Hypertension 58, 417-424 (2011).
97. Ciccone, M. M. et al. Reversibility of the endothelial dysfunction after CPAP therapy in OSAS patients. Int. J. Cardiol. 158, 383-386 (2012).
98. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B. & Castelli, W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561-1566 (1990).
99. Antony, I., Nitenberg, A., Foult, J. M. & Aptecar, E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J. Am. Coll. Cardiol. 22, 514-520 (1993).
100. Lembo, G. et al. Systemic hypertension and coronary artery disease: the link. Am. J. Cardiol. 82, 2H-7H (1998).
101. Vgontzas, A. N. et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab. 85, 1151-1158 (2000).
102. Hou, N. et al. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 37, 1087-1095 (2010).
103. Devereux, R. B. & Roman, M. J. in Hypertension: pathophysiology, diagnosis and management. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics (eds Laragh, J. H. & Brenner, B. M.) 409-432 (Raven Press Ltd, New York, 1995).
104. Schwartzkopff, B. et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88, 993-1003 (1993).
105. Belaidi, E. et al. Role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J. Am. Coll. Cardiol. 53, 1309-1317 (2009).
106. Park, A. M. & Suzuki, Y. J. Effects of intermittent hypoxia on oxidative stress-induced myocardial damage in mice. J. Appl. Physiol. 102, 1806-1814 (2007).
107. Park, A. M., Nagase, H., Kumar, S. V. & Suzuki, Y. J. Effects of intermittent hypoxia on the heart. Antioxid. Redox Signal. 9, 723-729 (2007).
108. Joyeux-Faure, M. et al. Chronic intermittent hypoxia increases infarction in the isolated rat heart. J. Appl. Physiol. 98, 1691-1696 (2005).
109. Ramond, A. et al. Oxidative stress mediates cardiac infarction aggravation induced by intermittent hypoxia. Fundam. Clin. Pharmacol. http://dx.doi.org/10.1111/j.1472-8206.2011.01015.x.
110. Young, T., Peppard, P. E. & Taheri, S. Excess weight and sleep-disordered breathing. J. Appl. Physiol. 99, 1592-1599 (2005).
111. Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Calverley, P. M. & Wilding, J. P. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur. Heart J. 25, 735-741 (2004).
112. Lee, S. D. et al. The coexistence of nocturnal sustained hypoxia and obesity additively increases cardiac apoptosis. J. Appl. Physiol. 104, 1144-1153 (2008).
113. Dela-Cruz, C. S. & Matthay, R. A. Role of obesity in cardiomyopathy and pulmonary hypertension. Clin. Chest Med. 30, 509-523 (2009).
114. Alpert, M. A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321, 225-236 (2001).
115. Leopoldo, A. S. et al. Involvement of L-type calcium channel and SERCA2a in myocardial dysfunction induced by obesity. J. Cell. Physiol. 226, 2934-2942 (2011).
116. Foster, G. D. et al. Sleep AHEAD Research Group. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 32, 1017-1019 (2009).
117. Borel, A. L. et al. High prevalence of obstructive sleep apnoea syndrome in a type 1 diabetic adult population: a pilot study. Diabet. Med. 27, 1328-1329 (2010).
118. Tahrani, A. A. et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am. J. Respir. Crit. Care Med. 186, 434-441 (2012).
119. Poornima, I. G., Parikh, P. & Shannon, R. P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605 (2006).
120. Mizushige, K. et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101, 899-907 (2000).
121. Ilercil, A. et al. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes 51, 1543-1547 (2002).
122. Iacobellis, G. et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes. Res. 11, 518-524 (2003).
123. Du, X. et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112, 1049-1057 (2003).
124. Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37, 1053-1059 (2001).
125. Drager, L. F., Bortolotto, L. A., Pedrosa, R. P., Krieger, E. M. & Lorenzi-Filho, G. Left atrial diameter is independently associated with arterial stiffness in patients with obstructive sleep apnea: potential implications for atrial fibrillation. Int. J. Cardiol. 144, 257-259 (2010).
126. Shinbane, J. S. et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J. Am. Coll. Cardiol. 29, 709-715 (1997).
127. Burchell, S. A., Spinale, F. G., Crawford, F. A., Tanaka, R. & Zile, M. R. Effects of chronic tachycardia-induced cardiomyopathy on the β-adrenergic receptor system. J. Thorac. Cardiovasc. Surg. 104, 1006-1012 (1992).
128. Spinale, F. G. et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am. J. Physiol. 261, H308-H318 (1991).
129. Sin, D. D. et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am. J. Respir. Crit. Care Med. 160, 1101-1106 (1999).
130. Shahar, E. et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 163, 19-25 (2001).
131. Hogg, K., Swedberg, K. & McMurray, J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J. Am. Coll. Cardiol. 43, 317-327 (2004).
132. Arias, M. A. et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function. Effects of nasal continuous positive airway pressure. Circulation 112, 375-383 (2005).
133. Niroumand, M., Kuperstein, R., Sasson, Z. & Hanly, P. J. Impact of obstructive sleep apnea on left ventricular mass and diastolic function. Am. J. Respir. Crit. Care Med. 163, 1632-1636 (2001).
134. Bradley, T. D., Hall, M. J., Ando, S. & Floras, J. S. Hemodynamic effects of simulated obstructive apneas in humans with and without heart failure. Chest 119, 1827-1835 (2001).
135. Lorell, B. H. & Carabello, B. A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102, 470-479 (2000).
136. Virolainen, J., Ventilä, M., Turto, H. & Kupari, M. Effect of negative intrathoracic pressure on left ventricular pressure dynamics and relaxation. J. Appl. Physiol. 79, 455-460 (1995).
137. Tavil, Y. et al. Comparison of right ventricular functions by tissue doppler imaging in patients with obstructive sleep apnea syndrome with or without hypertension. Int. J. Cardiovasc. Imaging 23, 469-477 (2007).
138. Brinker, J. A. et al. Leftward septal displacement during right ventricular loading in man. Circulation 61, 626-633 (1980).
139. Drager, L. F. et al. Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodelling. Chest 131, 1379-1386 (2007).